Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Research article

Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants

Ali A Alkhafaji12, Ludovic Trinquart1234, Gabriel Baron12, Moïse Desvarieux256 and Philippe Ravaud123456*

Author Affiliations

1 Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 1 place du parvis Notre Dame, Paris, 75004, France

2 INSERM U738, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 1 place du parvis Notre Dame, Paris, 75004, France

3 Université Paris Descartes - Sorbonne Paris Cité, 12 Rue de l'École de Médecine Paris, 75006, France

4 French Cochrane Centre, Hôpital Hôtel-Dieu, 1 place du parvis Notre Dame, Paris, 75004, France

5 EHESP School of Public Health, Avenue du Professeur Léon-Bernard, CS 74312, Rennes, 35043, France

6 Department of Epidemiology, Columbia University Mailman School of Public Health, 722 West 168th Street, New York, NY 10032, USA

For all author emails, please log on.

BMC Medicine 2012, 10:142  doi:10.1186/1741-7015-10-142

Published: 20 November 2012

Additional files

Additional file 1:

Section 1: Selection criteria and search strategy. Section 2: Methods and analysis details. Section 3: Selected trials. Section 4: Network analysis of trials for direct and indirect comparison and the number of trials in each comparison. Section 5: Characteristics of trials. Section 6: Characteristics of trials across different comparisons. Section 7: Consumption and cost analyses for the citalopram, generic citalopram, escitalopram from the French national health insurance information system. Section 8: Meta-analysis for efficacy data of head-to-head trials. Section 9: Funnel plot for efficacy data for head-to-head trials. Section 10: Meta-analysis for acceptability data for head-to-head trials. Section 11: Meta-analysis for efficacy data for placebo-controlled trials. Section 12: Funnel plot for efficacy data for placebo-controlled trials. Section 13: Meta-analysis for acceptability data for placebo-controlled trials. Section 14: Consumption levels (monthly no. of prescriptions) between 2003 and 2011 in France. Section 15: Consumption levels (monthly defined daily dose (DDD) units) between 2003 and 2011 in France. Section 16: Consumption levels for escitalopram versus citalopram and its generic forms combined. Section 17: Total consumption of escitalopram, citalopram and its generic forms.

Format: DOCX Size: 143KB Download file

Open Data